Insider Buying: GSK (LON:GSK) Insider Purchases 8 Shares of Stock

Key Points

• GSK insider Julie Brown purchased 8 shares of the company's stock on October 9th at an average cost of GBX 1,641 per share, totaling £131.28.
• On October 3rd, JPMorgan Chase & Co. reiterated an "under review" rating for GSK, while other brokerages maintained "hold" ratings with target prices ranging from GBX 1,450 to GBX 2,100.
• As of the last trading session, GSK shares fell 0.9% to GBX 1,625, with a market capitalization of £65.40 billion.

GSK plc (LON:GSK - Get Free Report) insider Julie Brown acquired 8 shares of the business's stock in a transaction on Thursday, October 9th. The shares were bought at an average cost of GBX 1,641 per share, with a total value of £131.28.

Julie Brown also recently made the following trade(s):

• On Tuesday, September 9th, Julie Brown bought 8 shares of GSK stock. The stock was acquired at an average cost of GBX 1,486 per share, with a total value of £118.88.
• On Monday, August 11th, Julie Brown acquired 9 shares of GSK stock. The shares were purchased at an average cost of GBX 1,408 per share, with a total value of £126.72.

GSK Trading Down 0.9%

Shares of LON:GSK traded down GBX 15 on Friday, hitting GBX 1,625. 6,694,230 shares of the company's stock were exchanged, compared to its average volume of 12,062,612. The company has a debt-to-equity ratio of 114.64, a current ratio of 0.81 and a quick ratio of 0.73. The business's 50 day simple moving average is GBX 1,483.79 and its two-hundred day simple moving average is GBX 1,438.37. The stock has a market capitalization of £65.40 billion, a price-to-earnings ratio of 1,964.93, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. GSK plc has a 12 month low of GBX 1,242.50 and a 12 month high of GBX 1,684.50.

GSK (LON:GSK - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The company reported GBX 75.30 earnings per share for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. Analysts anticipate that GSK plc will post 175.980975 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have commented on GSK. JPMorgan Chase & Co. reiterated an "under review" rating on shares of GSK in a report on Friday, October 3rd. Berenberg Bank reiterated a "hold" rating and issued a GBX 1,600 target price on shares of GSK in a report on Friday, July 18th. Shore Capital restated a "buy" rating and set a GBX 2,100 price objective on shares of GSK in a report on Wednesday, August 27th. Finally, Deutsche Bank Aktiengesellschaft reiterated a "hold" rating and issued a GBX 1,450 target price on shares of GSK in a research report on Thursday, July 31st. One analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average price target of GBX 1,637.50.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.